Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 M2rocGtqdmG|ZTDBd5NigQ>? MnvyNlQhcA>? NYHtV41PUW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2= NIDDcoMzPDZ2MUGwNy=>
COLO205 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\NSFVDPzJiaB?= NIDxVmFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>? NXixVlJDOjR4NEGxNFM>
U937 M1;zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NkBp MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN M{K3NFI1PjRzMUCz
MOLM13 NIDXNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT2VGltPzJiaB?= NGHKO|ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{Bp[XKkb4LpcochTkyWMzDJWGQhdXW2YX70JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO M4jjSlI1PjRzMUCz
MOLM13 NXX6Z|c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVS3NkBp M{XpfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sgd49z[W[nbnniMZJme2m|dHHueEBpfW2jbjDNU2xOOTNiY3XscJMh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkC5OkDPxE1? NV7URoM1OjR4NEGxNFM>
MDA-MB-435 NWLWcVljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXSNlQhcA>? M{LoOWlEPTB;MD6xOkDPxE1? MmmwNVU5ODF6M{G=
K562 NGm1em1EgXSxdH;4bYMhSXO|YYm= MX[5OkBp MYLEUXNQ MlHkTWM2OD1{IN88US=> M2OxXlI1PDF5NU[2
DU145 NH7CNYZEgXSxdH;4bYMhSXO|YYm= MnrwPVYhcA>? NHfIR25FVVOR NWf1NHptUUN3ME23MlUh|ryP NHmyZoczPDRzN{W2Oi=>
MDA-MB-231 Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r6blEh|ryP NYPCXJlkOjRiaB?= MoS1SG1UVw>? NWDNNJVpS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm MWGyOFQyPzV4Nh?=
MCF7 M4DSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn61NUDPxE1? NFP3S48zPCCq M4nI[GROW09? NHm4NHdE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> M1LyR|I1PDF5NU[2
MCF7 NHzEUlJMcW6jc3WgRZN{[Xl? NWqwdoRDPSEQvF2= NXLCb|QyOjRiaB?= Mn3JSG1UVw>? MnfKTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= MoDJNlQ1OTd3Nk[=
MDA-MB-231 NHy0dJBMcW6jc3WgRZN{[Xl? M174PVUh|ryP MlrWNlQhcA>? NF\MbGtFVVOR NXHibmtiUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> MnfBNlQ1OTd3Nk[=
MDA-MB-231 NXXWXXF3TnWwY4Tpc44hSXO|YYm= MXSxMVExKM7:TR?= MWKyOEBp Mn\sSG1UVw>? NX3XcWc{\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl MljSNlQ1OTd3Nk[=
MCF7 NE\4VYpHfW6ldHnvckBCe3OjeR?= MnrKNU0yOCEQvF2= MlHKNlQhcA>? M1zNVmROW09? MVHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? NFzCPYszPDRzN{W2Oi=>
MDA-MB-231 Mmq2SpVv[3Srb36gRZN{[Xl? MUWwMlUuOSEQvF2= MUm0PEBp MWjEUXNQ M{\VTYhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm MmDrNlQ1OTd3Nk[=
MCF7 MkXQSpVv[3Srb36gRZN{[Xl? NFHTU|MxNjVvMTFOwG0> NV;RRYxHPDhiaB?= NIftO3RFVVOR NH3Ec4xp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? Mn3pNlQ1OTd3Nk[=
697 NXP3cG17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj2VWRKSzVyPUG0PE4{QCCwTR?= MVrTRW5ITVJ?
P12-ICHIKAWA MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi3TWM2OD17Nj6wOEBvVQ>? NXjMVZh{W0GQR1XS
NB69 M4jGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jFN2lEPTB;MU[xMlghdk1? M4DXPHNCVkeHUh?=
EoL-1 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\0XWFKSzVyPUG4O{4zPiCwTR?= M1SyXHNCVkeHUh?=
BHT-101 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF7OD6yOUBvVQ>? MYXTRW5ITVJ?
SK-NEP-1 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLRTWM2OD1{MkCuNFIhdk1? NYjES2UyW0GQR1XS
MHH-NB-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ{MD6xPUBvVQ>? NUfIT5M2W0GQR1XS
AsPC-1 NVfHNIJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj4TWM2OD1{NUKuOVMhdk1? M4LQfHNCVkeHUh?=
ES1 NYrDSmZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFexeVJKSzVyPUK1Ok4zPSCwTR?= NGXHSoVUSU6JRWK=
LAMA-84 NUjZT4pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULUVJFjUUN3ME2yOVgvOTlibl2= NWTWV3M4W0GQR1XS
MOLT-16 NFPTN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzWVphwUUN3ME2yOVgvPDlibl2= MlW0V2FPT0WU
ES7 M1TUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn0TXlnUUN3ME2yO|MvODlibl2= Mo\QV2FPT0WU
KY821 NVrWOlRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\OSmlEPTB;M{G0MlEhdk1? MUHTRW5ITVJ?
RT-112 M4OxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDmVndKSzVyPUOyNU4xPSCwTR?= NWXxfY9sW0GQR1XS
HL-60 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jsbGlEPTB;M{SwMlY3KG6P MojhV2FPT0WU
MOLT-4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHlR2JSUUN3ME2zOFUvOTNibl2= MVTTRW5ITVJ?
KARPAS-45 NV;0UmZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN5Nj6xOkBvVQ>? M3XBb3NCVkeHUh?=
SK-N-AS MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVqze5hSUUN3ME2zPFcvQDNibl2= MlzBV2FPT0WU
CTB-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3yTWM2OD12MEWuNFIhdk1? NWrVV3dGW0GQR1XS
NKM-1 M1\te2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DYNWlEPTB;NEGxMlg6KG6P Mm\wV2FPT0WU
HTC-C3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr4TWM2OD12M{KuPVUhdk1? M1LPc3NCVkeHUh?=
BE-13 NEnnOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTR2ND6yO{BvVQ>? MluyV2FPT0WU
KOSC-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXKSmVPUUN3ME20OlYvQSCwTR?= MnTiV2FPT0WU
NB14 NHr3R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TUTWlEPTB;NEizMlU5KG6P Mke1V2FPT0WU
CAL-27 M{Dzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTCb3RKSzVyPUS5OE42QSCwTR?= MlHJV2FPT0WU
H9 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvuOG5KSzVyPUS5OU41OyCwTR?= NFG5OXhUSU6JRWK=
RS4-11 NUi2SGw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTVyND63N{BvVQ>? MnHOV2FPT0WU
PA-1 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni4TWM2OD13MEmuPFYhdk1? MW\TRW5ITVJ?
MV-4-11 NUDHVVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz1UHZIUUN3ME21NVMvQDVibl2= MX;TRW5ITVJ?
OS-RC-2 M4TCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi5bZNoUUN3ME21NlEvPjJibl2= M{LVVHNCVkeHUh?=
RPMI-8226 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S2OGlEPTB;NUK2Mlg3KG6P MmrIV2FPT0WU
HGC-27 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXXTWM2OD13NkSuPVkhdk1? MnfLV2FPT0WU
CHP-212 NEfFN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkOzTWM2OD13OUOuOVkhdk1? MlfmV2FPT0WU
NB10 NX\FTIJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLwe|NlUUN3ME21PVkvOThibl2= M2HJUnNCVkeHUh?=
HH NGjq[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;ENG5KSzVyPUW5PU41OyCwTR?= NXXvWpNGW0GQR1XS
EW-16 NGjEUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvXRoxSUUN3ME22NFMvPTJibl2= M2LlZ3NCVkeHUh?=
ES8 NE\3OFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm3Z4ZbUUN3ME22NFUvOjFibl2= MUDTRW5ITVJ?
HAL-01 NVHuV49uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTZyNT62O{BvVQ>? MlTOV2FPT0WU
A204 NWnCbGVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\zfmdwUUN3ME22N|MvQTFibl2= M1TJdHNCVkeHUh?=
MHH-PREB-1 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTuRYZKSzVyPU[zOk46QSCwTR?= M1znWHNCVkeHUh?=
EM-2 M3\KU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LKZ2lEPTB;NkWwMlY1KG6P Mlv6V2FPT0WU
BV-173 M120cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTGNXpKSzVyPU[1Nk41QCCwTR?= NES0NHRUSU6JRWK=
ONS-76 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:yNmlEPTB;Nke3MlgzKG6P MWXTRW5ITVJ?
KM-H2 M1W2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTZ7NT61OEBvVQ>? MUfTRW5ITVJ?
D-263MG NVrV[2dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXRTWM2OD15MUeuNVIhdk1? NXXJfpJXW0GQR1XS
ES3 NVvy[FFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PxdWlEPTB;N{K4Mlk{KG6P MUHTRW5ITVJ?
VA-ES-BJ M4XuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPFdGlKSzVyPUezNk4zPyCwTR?= M4TXc3NCVkeHUh?=
NBsusSR MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TxWmlEPTB;N{SyMlk6KG6P MnTUV2FPT0WU
NCI-H520 NYK3cmdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfJTWM2OD15NE[uOVIhdk1? MlPuV2FPT0WU
ES5 MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPSTWM2OD15NUKuPEBvVQ>? MUjTRW5ITVJ?
T-24 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TBZWlEPTB;N{e4MlcyKG6P M{L1SHNCVkeHUh?=
SW962 NUXQdnJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD3TWM2OD16MEiuOlMhdk1? M2rKOXNCVkeHUh?=
EW-3 NVOxUphNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\CTZJKSzVyPUiwPE44PiCwTR?= M{jSZXNCVkeHUh?=
RXF393 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDpS4tQUUN3ME24NVIvPzlibl2= MlfmV2FPT0WU
U251 M4nmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT3PFNXUUN3ME24NVMvQDhibl2= MYDTRW5ITVJ?
CAMA-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrOU|hKSzVyPUizN{46PCCwTR?= Mn7zV2FPT0WU
JVM-3 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:4OmlEPTB;OEWxMlc5KG6P M1vYOXNCVkeHUh?=
COLO-800 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPZWVVKSzVyPUi5O{44QCCwTR?= NEfRRXRUSU6JRWK=
OVCAR-5 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XXN2lEPTB;OUCwMlEhdk1? M4nHS3NCVkeHUh?=
LB1047-RCC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzXTWM2OD17MkeuOVYhdk1? MkPVV2FPT0WU
SW954 M4rmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HINWlEPTB;OUK5MlQyKG6P M2PJO3NCVkeHUh?=
J-RT3-T3-5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvtcIhKSzVyPUmzOk4xPiCwTR?= M1i2WXNCVkeHUh?=
Mewo MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXzfopIUUN3ME25N|YvPiCwTR?= MVfTRW5ITVJ?
NCI-H1770 NGDSRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe5dJNmUUN3ME25OFAvPTVibl2= NHK5VHdUSU6JRWK=
HO-1-N-1 NV3vSVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7PTWM2OD17NkKuPFEhdk1? MVzTRW5ITVJ?
HSC-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXyzeldWUUN3ME25OlYvPDhibl2= MWTTRW5ITVJ?
TYK-nu MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVntWFBiUUN3ME25PVgvOjVibl2= MVfTRW5ITVJ?
KYSE-150 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvpcI9KSzVyPUGuNFAxPzZizszN NF7TVXpUSU6JRWK=
SN12C NV7GVHpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;0XWlEPTB;MT6wNFg4PSEQvF2= MmTwV2FPT0WU
MOLT-13 M372VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwMEG0NlEh|ryP MlrzV2FPT0WU
TE-11 NITXO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P0OmlEPTB;MT6wOFgyOiEQvF2= NGTSXoVUSU6JRWK=
DB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[wTWM2OD1zLkC3Nlc{KM7:TR?= Ml3xV2FPT0WU
CAL-39 NGrCfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV36V45tUUN3ME2xMlA4PTJ{IN88US=> NUP6cnVtW0GQR1XS
A3-KAW MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWTWM2OD1zLkC4OFA5KM7:TR?= MUXTRW5ITVJ?
CHP-134 MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DtVGlEPTB;MT6xNVgxPyEQvF2= NVL1VJR{W0GQR1XS
TGW NXHIR3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTaNmpKSzVyPUGuNVI{QTVizszN MljlV2FPT0WU
QIMR-WIL M1TseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwMUOxN|Qh|ryP NIHOSIJUSU6JRWK=
NCI-SNU-1 NX[2blh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{no[mlEPTB;MT6xOlM2PCEQvF2= MkjiV2FPT0WU
CGTH-W-1 NV\JSHJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwMUexPFYh|ryP M2S2cHNCVkeHUh?=
MHH-ES-1 M1uxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTMVJdKSzVyPUGuNVc6QDZizszN NF:zXHZUSU6JRWK=
LB2241-RCC NGe4fWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7SdW1KSzVyPUGuNVg3OiEQvF2= NVmyeWsxW0GQR1XS
ML-2 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlznTWM2OD1zLkKwO|M1KM7:TR?= MV\TRW5ITVJ?
COR-L23 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLUTWM2OD1zLkKyPVM{KM7:TR?= Mn31V2FPT0WU
BFTC-905 NHqzXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvqUYw6UUN3ME2xMlI1OjZ5IN88US=> MnzSV2FPT0WU
Hs-578-T M3P3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXwbGROUUN3ME2xMlI2QDF5IN88US=> Mn6xV2FPT0WU
KG-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwMk[2PFYh|ryP M3XvcHNCVkeHUh?=
HEL M1LH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfRSm1XUUN3ME2xMlI6OzN6IN88US=> MXLTRW5ITVJ?
A549 MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTKTWM2OD1zLkK5N|k6KM7:TR?= Mlv3V2FPT0WU
COLO-741 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFwM{KwPFkh|ryP Mn3ZV2FPT0WU
PC-3 M2njPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwM{WyNlEh|ryP MXLTRW5ITVJ?
HOS Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvCTZNKSzVyPUGuN|UzQTZizszN MWTTRW5ITVJ?
HT-1080 NX3nR24{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTOTWM2OD1zLkO3OVE6KM7:TR?= MmTvV2FPT0WU
TE-8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwNEG3O|Qh|ryP M37ZZ3NCVkeHUh?=
BHY MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Xld2lEPTB;MT60OlkzOyEQvF2= Mn7oV2FPT0WU
BB65-RCC NXvKd2FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwNUC1Nlgh|ryP M3HGU3NCVkeHUh?=
HN MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK5NWVEUUN3ME2xMlU1ODdzIN88US=> MmTzV2FPT0WU
NCI-H441 M2nl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHmfmJKSzVyPUGuOVQ6ODdizszN MVPTRW5ITVJ?
RPMI-8866 NY\VTWlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XTc2lEPTB;MT61PFUxPyEQvF2= NEPGPFBUSU6JRWK=
CAL-62 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TRbmlEPTB;MT62NFg3OiEQvF2= NYS3UFhpW0GQR1XS
MG-63 NHvtXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TTbWlEPTB;MT62NVgyOyEQvF2= M1\TXnNCVkeHUh?=
SK-LU-1 NYH1VoR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\vTWM2OD1zLk[yNVUzKM7:TR?= MYXTRW5ITVJ?
BCPAP MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDpd|ljUUN3ME2xMlY3PDV5IN88US=> MVHTRW5ITVJ?
22RV1 NFrndGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwNke4OFMh|ryP MVXTRW5ITVJ?
T47D Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne0TWM2OD1zLk[4NFYyKM7:TR?= NFTxZ5pUSU6JRWK=
MSTO-211H NYTrRZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwNkm2NFMh|ryP MlXRV2FPT0WU
DEL NX3XNJU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwN{CyO|Mh|ryP NITlVFFUSU6JRWK=
H4 Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LpdmlEPTB;MT63N|IyOiEQvF2= NUHqNJA1W0GQR1XS
CAL-51 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwN{S4OVUh|ryP M{fN[XNCVkeHUh?=
ABC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf5fppKSzVyPUGuO|g2QDJizszN MnTSV2FPT0WU
MZ2-MEL NFnndpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLudpFiUUN3ME2xMlc6PTR{IN88US=> NG[z[IRUSU6JRWK=
YKG-1 NWP0WXVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTJTWM2OD1zLkixNFYyKM7:TR?= NWXkbpRSW0GQR1XS
KM12 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrWeFFKSzVyPUGuPFE3ODJizszN MlG3V2FPT0WU
L-363 NUS3W3VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn2TWM2OD1zLki3OFEzKM7:TR?= NFLnR4RUSU6JRWK=
KU812 NHG0b4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nXVWlEPTB;MT64PVI5OiEQvF2= NEP4T|BUSU6JRWK=
LOXIMVI M2PaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfsTWM2OD1zLkmxNlI5KM7:TR?= MkPhV2FPT0WU
G-401 NVS5[JUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[xS3pGUUN3ME2xMlkzPDJ6IN88US=> NHy0d|dUSU6JRWK=
SW780 NFXZeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwOU[yOFYh|ryP NIfJdIVUSU6JRWK=
SW872 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HxT2lEPTB;MT65PFM{KM7:TR?= MmjZV2FPT0WU
NB7 M2LXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW2TWM2OD1zLkm5N|I{KM7:TR?= MnXEV2FPT0WU
T98G NXfCfYRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrlNpRKSzVyPUKuNFA3PjZizszN MXzTRW5ITVJ?
SW1710 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf2TWM2OD1{LkC2PVQ2KM7:TR?= M2HKcnNCVkeHUh?=
NCI-H1573 M4XYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXhTWlkUUN3ME2yMlA4Ojl6IN88US=> MlPjV2FPT0WU
KE-37 NXXkcWY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH33T2pKSzVyPUKuNFg6PTFizszN NEjObY5USU6JRWK=
786-0 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PKdGlEPTB;Mj6xOVQ{QSEQvF2= NVjYVZJxW0GQR1XS
SAS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLUVGJ3UUN3ME2yMlIxOzd2IN88US=> NGmxOHJUSU6JRWK=
CAL-54 MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC3TWM2OD1{LkKwOFE{KM7:TR?= NX3OXGRqW0GQR1XS
SF268 M2jQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fzWmlEPTB;Mj6yN|EzOiEQvF2= MUTTRW5ITVJ?
SW620 MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwMk[xOlkh|ryP NXO2fphKW0GQR1XS
MN-60 M1mxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq4TWM2OD1{LkOxNFYh|ryP NGfqOVdUSU6JRWK=
EFO-27 MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TyRWlEPTB;Mj6zNlA2QCEQvF2= NEDYS3hUSU6JRWK=
NCI-H747 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\UVIVbUUN3ME2yMlMzOTl7IN88US=> MlnyV2FPT0WU
HCC2218 M2nCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S5WWlEPTB;Mj6zOVM4PCEQvF2= MVrTRW5ITVJ?
MIA-PaCa-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3mTWM2OD1{LkO2OFM4KM7:TR?= MYLTRW5ITVJ?
SJSA-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnETWM2OD1{LkO3O|k3KM7:TR?= NGC4SI9USU6JRWK=
RKO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnEN2ZKSzVyPUKuN|g1QTZizszN MYrTRW5ITVJ?
NB6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwNECzO|Qh|ryP M3u2OnNCVkeHUh?=
ES4 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFOxU4JKSzVyPUKuOFU1OjJizszN M1PxSHNCVkeHUh?=
EGI-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHrNG9VUUN3ME2yMlQ3QDh|IN88US=> NYHS[FNnW0GQR1XS
CTV-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXkTWM2OD1{LkWyO|c{KM7:TR?= MoPxV2FPT0WU
NCI-H1355 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;hfWFKSzVyPUKuOVU6PTFizszN MW\TRW5ITVJ?
GT3TKB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJwNUmxPVkh|ryP NFu0R2hUSU6JRWK=
SK-HEP-1 NGj6bYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjJO3hKSzVyPUKuOVkzPjZizszN NIfsfGhUSU6JRWK=
GAMG MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLlWIFyUUN3ME2yMlU6Ozl2IN88US=> MVPTRW5ITVJ?
SK-MES-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJwNkG4NFMh|ryP NHjSN2hUSU6JRWK=
RO82-W-1 M4f3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwNkKwOVch|ryP NYr6PGNzW0GQR1XS
ECC10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTzUnp1UUN3ME2yMlcxOjB4IN88US=> NXnhTYV2W0GQR1XS
MCF7 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK3PY1KSzVyPUKuO|E1PjRizszN NUTNW3hpW0GQR1XS
D-283MED MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3pTHNXUUN3ME2yMlczPDNizszN MXLTRW5ITVJ?
RPMI-7951 NH7hfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rWfWlEPTB;Mj63OVY6PCEQvF2= Mkf6V2FPT0WU
Ramos-2G6-4C10 M{nSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjXe21KSzVyPUKuO|cxQTlizszN NFThWppUSU6JRWK=
KGN Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m5VmlEPTB;Mj64NVg5PCEQvF2= M4G3R3NCVkeHUh?=
NUGC-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPZSnhUUUN3ME2yMlgzPTB3IN88US=> NI\lTYRUSU6JRWK=
NCI-H292 NEPQZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofXTWM2OD1{Lki1NFU{KM7:TR?= NE\XR2tUSU6JRWK=
Becker NX\FUVBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vu[mlEPTB;Mj65OVg{OiEQvF2= MmPYV2FPT0WU
NCI-H1299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCwTWM2OD1|LkC1NlY{KM7:TR?= NX21fVhNW0GQR1XS
ETK-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\BOFFYUUN3ME2zMlA2PDNizszN NXz3d|FPW0GQR1XS
TK10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nCS2lEPTB;Mz6yNFE3PSEQvF2= M3\ufXNCVkeHUh?=
VMRC-RCZ NHnyVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq3eHpKSzVyPUOuN|Y1QDhizszN M4TIVXNCVkeHUh?=
YH-13 M{LSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwNESwO|kh|ryP Ml;QV2FPT0WU
DU-145 M3XGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXFTWM2OD1|LkS2NlY6KM7:TR?= NF3HO|BUSU6JRWK=
SW1088 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO4enBKSzVyPUOuOFc1PyEQvF2= NUnDOY1JW0GQR1XS
HOP-92 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNwNUCzOFIh|ryP MV3TRW5ITVJ?
KP-N-YS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm1TlVOUUN3ME2zMlYzOTN7IN88US=> MYnTRW5ITVJ?
NCI-H460 M1\5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLaTWM2OD1|Lk[2O|Mh|ryP MX3TRW5ITVJ?
U-2-OS MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnuNWs{UUN3ME2zMlczPTN3IN88US=> NUfDXpNpW0GQR1XS
A101D M1qxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwN{[5N|Yh|ryP M4DCc3NCVkeHUh?=
MDA-MB-231 NFPzWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXMTWM2OD1|LkixPVUyKM7:TR?= NHu0eXFUSU6JRWK=
IST-MES1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3WNmtKSzVyPUOuPFMzKM7:TR?= MW\TRW5ITVJ?
COR-L105 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq4TWM2OD12LkCxPEDPxE1? NEPrNmNUSU6JRWK=
NCI-H1437 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfLUmFKSzVyPUSuNFI{ODJizszN MUDTRW5ITVJ?
CAL-85-1 M1zEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHITWM2OD12LkCyOFYyKM7:TR?= M1q0NXNCVkeHUh?=
MZ1-PC NG\PPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37qO2lEPTB;ND6xPFU2PiEQvF2= MoXlV2FPT0WU
VM-CUB-1 NGjJRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K3OGlEPTB;ND6zNVI5PCEQvF2= MlvaV2FPT0WU
CHL-1 M3XxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO5TWM2OD12LkOyNVY6KM7:TR?= NH3ENXFUSU6JRWK=
MDA-MB-361 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTRwM{OxOVMh|ryP NV32TlJbW0GQR1XS
NCI-H661 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHPfHczUUN3ME20MlUxODl{IN88US=> MnPtV2FPT0WU
EW-11 NVTkXZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\pPGlEPTB;ND61NlI{OSEQvF2= MlryV2FPT0WU
BEN NFnzeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwNUK4NVUh|ryP NVni[XIxW0GQR1XS
BFTC-909 M1zme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjNTWM2OD12LkW2Nlc2KM7:TR?= MWfTRW5ITVJ?
NCI-H2087 NHnDcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DzVWlEPTB;ND61PFE3PCEQvF2= MXfTRW5ITVJ?
RVH-421 NWS2Z29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjKTW1KSzVyPUSuOlY3QSEQvF2= M2m1fHNCVkeHUh?=
P30-OHK MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzVdWhKSzVyPUSuOlgxODhizszN NXHqfZZ7W0GQR1XS
NCI-H28 M4W3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjUUnFKSzVyPUSuPFE3PjFizszN NHLRSXNUSU6JRWK=
ES6 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XqXmlEPTB;ND64N|AyPiEQvF2= MVXTRW5ITVJ?
769-P M1zQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\FcIdzUUN3ME20Mlg2QTJ4IN88US=> NYLTWJExW0GQR1XS
OE33 NH[yOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr6OWpbUUN3ME20Mlg5OTZzIN88US=> NHv5TFVUSU6JRWK=
SW982 NITyTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP0TWM2OD12Lkm1NFYyKM7:TR?= MVrTRW5ITVJ?
A388 M3nKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjy[lJKSzVyPUWuNFI6QDNizszN MUPTRW5ITVJ?
TI-73 NYix[4ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTKTWM2OD13LkC2NVk1KM7:TR?= MXnTRW5ITVJ?
HCT-116 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETkU5hKSzVyPUWuNFk5QDlizszN MV3TRW5ITVJ?
HuP-T3 NInJV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTVwMUi3NFkh|ryP MXXTRW5ITVJ?
G-402 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTVwMUm0NVYh|ryP NWnDS4dNW0GQR1XS
NCI-H1792 NX\w[ldxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrXTWM2OD13LkK0OlIzKM7:TR?= M{PHWHNCVkeHUh?=
NCI-H209 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTVwMkW5OFIh|ryP NIXuWVVUSU6JRWK=
NCI-H1650 M{n4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoiwTWM2OD13LkOwOlM1KM7:TR?= MoL2V2FPT0WU
LCLC-97TM1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTVwM{G4NFgh|ryP NFXxfplUSU6JRWK=
S-117 NFfRdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\qR|JKSzVyPUWuN|Y6PzZizszN NVfoVHlRW0GQR1XS
GI-ME-N M4f4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTVwM{m2PFEh|ryP MXLTRW5ITVJ?
NCI-H2122 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTVwNEmzPVch|ryP MoTNV2FPT0WU
NCI-H1793 NVLOS4VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTVwNke1PVMh|ryP M3vtN3NCVkeHUh?=
C2BBe1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTVwN{CwPFgh|ryP M4TXbHNCVkeHUh?=
TE-12 NFSwXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vmRWlEPTB;NT64NFU2PiEQvF2= NHjnUVdUSU6JRWK=
LCLC-103H MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTVwOUG3JO69VQ>? MmTIV2FPT0WU
A673 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DrSmlEPTB;NT65NVk{OiEQvF2= MkDLV2FPT0WU
BB30-HNC MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfzUIR4UUN3ME21Mlk5OzZizszN MkLBV2FPT0WU
SF295 M4i3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;JTWM2OD14LkCwOFIzKM7:TR?= NUi4Z25sW0GQR1XS
KU-19-19 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr6O2hUUUN3ME22MlAyPzNzIN88US=> NXHWRZY2W0GQR1XS
CFPAC-1 M4\0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrLVXZKSzVyPU[uNFQ1PDNizszN MnftV2FPT0WU
LoVo NEPPU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7JcohkUUN3ME22MlA2ODZ|IN88US=> NUnk[GRZW0GQR1XS
8505C M3H2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NESwN4JKSzVyPU[uNFc2PzNizszN NH73eW5USU6JRWK=
GMS-10 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTIWnpKSzVyPU[uNVUxODJizszN M4juUnNCVkeHUh?=
Ca9-22 M1W1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vWXmlEPTB;Nj6xOlcyKM7:TR?= M2H4b3NCVkeHUh?=
DOK M{XhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTZwMkKwO|Ih|ryP M{D2W3NCVkeHUh?=
FADU MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzoTWM2OD14LkK2NFM6KM7:TR?= NHPPRWtUSU6JRWK=
BxPC-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX6TWM2OD14LkK3N|Ih|ryP MnfFV2FPT0WU
CAL-33 NIXlWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TEeWlEPTB;Nj6yPVIxOSEQvF2= MmLkV2FPT0WU
SHP-77 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\JTWM2OD14LkOxOVEzKM7:TR?= NF;o[XNUSU6JRWK=
LXF-289 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HjNWlEPTB;Nj6zN|Q2PSEQvF2= Mmf6V2FPT0WU
GB-1 NUnRSHRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\T[VNPUUN3ME22MlM5OiEQvF2= MVPTRW5ITVJ?
KS-1 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D3bGlEPTB;Nj6zPFQ1PyEQvF2= NV[3[XJzW0GQR1XS
D-502MG NWfwWmZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PQfGlEPTB;Nj60NlM4PiEQvF2= M2m1e3NCVkeHUh?=
LAN-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XsdWlEPTB;Nj61NVAzOyEQvF2= MmfhV2FPT0WU
H-EMC-SS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTZwNU[xOFch|ryP NXm3UHoyW0GQR1XS
LC-2-ad NU\T[GtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTZwNkCwO|Yh|ryP MWTTRW5ITVJ?
NCI-H1693 NGjQTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjVTWM2OD14Lk[yNlE2KM7:TR?= MnTuV2FPT0WU
SK-N-FI MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zuOWlEPTB;Nj63OVA1PCEQvF2= M3zPenNCVkeHUh?=
D-423MG M2e5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHDTWM2OD14Lke2NVE4KM7:TR?= M3rJ[HNCVkeHUh?=
KNS-42 MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTZwN{ixPVch|ryP NF75d5hUSU6JRWK=
GCT MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTZwOUO4JO69VQ>? Ml7TV2FPT0WU
DSH1 M174W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTdwME[zN{DPxE1? M1HJUHNCVkeHUh?=
D-247MG M2Tl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTdwMEe4PFEh|ryP NU[yNXBkW0GQR1XS
NCI-SNU-5 NYq0T|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HPZ2lEPTB;Nz6xPFM4OSEQvF2= M3z1UXNCVkeHUh?=
TE-6 NH;TZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X2cGlEPTB;Nz6yNFYxOSEQvF2= M322TXNCVkeHUh?=
NOMO-1 NGD5dZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXRTWM2OD15LkKyNVI4KM7:TR?= Mof2V2FPT0WU
NB17 MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV63SFJMUUN3ME23MlMxOzB7IN88US=> NUmx[HJjW0GQR1XS
EW-22 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37zO2lEPTB;Nz6zOFM1QCEQvF2= NGPTPXZUSU6JRWK=
EW-13 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTdwM{WxOlIh|ryP MXfTRW5ITVJ?
DOHH-2 NGD6RodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTdwNESwNkDPxE1? MXHTRW5ITVJ?
TGBC1TKB M2THPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTdwNEm4PVkh|ryP MoeyV2FPT0WU
GR-ST NEO1[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK0WGlKSzVyPUeuOVI2QTRizszN MYPTRW5ITVJ?
KYSE-520 NU[0UZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnVdYFyUUN3ME23MlU2PTF3IN88US=> M1jIR3NCVkeHUh?=
CAPAN-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwNUm1NUDPxE1? NV63WHJMW0GQR1XS
HCE-4 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\6SVhKSzVyPUeuOlIzPzlizszN MojwV2FPT0WU
MLMA NIPjfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzCPW5KSzVyPUeuOlI6PTdizszN MorLV2FPT0WU
HT-144 NYjBd25WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTdwNkWzOlgh|ryP MoTDV2FPT0WU
KYSE-180 M4XGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXSWJhKSzVyPUeuO|EyPjlizszN NGnteHJUSU6JRWK=
TE-5 NH7teIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTRNFNKSzVyPUeuPVU6PzFizszN MX3TRW5ITVJ?
IGROV-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\QTWM2OD15Lkm4OVUyKM7:TR?= MmLsV2FPT0WU
NCI-H1581 NXvYV3g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;OVmlEPTB;OD6wNVIh|ryP NYXnfmxRW0GQR1XS
SW1990 Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;jOYZKSzVyPUiuNFQ3PTlizszN NFLq[3hUSU6JRWK=
EFM-19 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHITWM2OD16LkC4OVQ2KM7:TR?= NGr4dHdUSU6JRWK=
OGR-1 M1r4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi0b4ZYUUN3ME24MlQ{ODJ|IN88US=> MU\TRW5ITVJ?
U-118-MG MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThwNEO0OlMh|ryP NH7HTlJUSU6JRWK=
SK-OV-3 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIizV5FKSzVyPUiuOFY4PjVizszN NX3ycG1GW0GQR1XS
KNS-62 NYrSfWJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjWXGVuUUN3ME24MlUyPzZzIN88US=> Ml;WV2FPT0WU
GOTO NG\ocnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRThwNUe2N|Uh|ryP MmrYV2FPT0WU
8305C Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHT1V4xKSzVyPUiuO|A1QDRizszN NUWxSJhWW0GQR1XS
RPMI-2650 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HaUGlEPTB;OD63NVk2PSEQvF2= NWnJT4VWW0GQR1XS
NEC8 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3znZmlEPTB;OD63OFMxPyEQvF2= M3\FbnNCVkeHUh?=
KYSE-450 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDuXlljUUN3ME24Mlg3PTR6IN88US=> MYTTRW5ITVJ?
RMG-I NGm4NHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTlwMUSwOVgh|ryP MULTRW5ITVJ?
CAKI-1 M4X5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOzV4cxUUN3ME25MlMyQTd7IN88US=> MkPDV2FPT0WU
KYSE-510 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fZN2lEPTB;OT6zOVc4QCEQvF2= MYfTRW5ITVJ?
A4-Fuk MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTlwM{[3NFEh|ryP NV;4cWZIW0GQR1XS
AN3-CA M{fJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEeycXZKSzVyPUmuOFU1PDRizszN MlzIV2FPT0WU
SK-N-DZ MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml22TWM2OD17LkeyPFQ6KM7:TR?= M4ribHNCVkeHUh?=
HSC-2 NIPsbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTlwN{[2Nlkh|ryP NFr4Zo1USU6JRWK=
EW-1 NWn2VoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKyTWM2OD17Lke5N|Y6KM7:TR?= NIrSWnlUSU6JRWK=
D-566MG NFX4foRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[4bmNKSzVyPUmuPFM3PjRizszN MYnTRW5ITVJ?
COLO-792 M2TzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrYUGJGUUN3ME25Mlk5PzR4IN88US=> NFvOT4tUSU6JRWK=
TE-10 M{\zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DVdWlEPTB;MUCuNFM6PiEQvF2= NX7ncJF{W0GQR1XS
NCI-H650 NH7jXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFyLkSyPFYh|ryP NEHI[W5USU6JRWK=
U-266 M{jSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrNTWM2OD1zMD60OVUh|ryP MUfTRW5ITVJ?
Detroit562 NIfr[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LqNWlEPTB;MUGuNFUyPSEQvF2= NVv0VZNoW0GQR1XS
NH-12 NGXRTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M176T2lEPTB;MUGuNVQ1PiEQvF2= M{GzVXNCVkeHUh?=
CO-314 NHHLXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzQTWM2OD1zMT6yPFQzKM7:TR?= MnrTV2FPT0WU
IST-MEL1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WzcGlEPTB;MUGuOVMzOyEQvF2= NXHkPFFmW0GQR1XS
KNS-81-FD Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHa[YpKSzVyPUGxMlU2OjdizszN Mn3pV2FPT0WU
SW1463 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37YT2lEPTB;MUGuOVk5QSEQvF2= MWfTRW5ITVJ?
NCI-H23 NHXwU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzzdmFKSzVyPUGxMlY2PTJizszN NWXENJpxW0GQR1XS
SK-MEL-2 NYPHeWRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P4[2lEPTB;MUGuO|E6PyEQvF2= NGj6UFBUSU6JRWK=
NB13 NXzqUWNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPVcZdKSzVyPUGyMlE1QTVizszN Mn;HV2FPT0WU
Daoy MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT2RYhKSzVyPUGyMlI5PTZizszN NUT4[oxlW0GQR1XS
NCI-H1623 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHrXmhKSzVyPUGyMlM5ODFizszN M1rTVHNCVkeHUh?=
NMC-G1 M4nXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HsXWlEPTB;MUKuO|E4KM7:TR?= M17UW3NCVkeHUh?=
DK-MG NGDQS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXZTWM2OD1zMj65OFgzKM7:TR?= M{XpVXNCVkeHUh?=
TCCSUP NUe5NFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKyb3RKSzVyPUGzMlEzQDRizszN MXjTRW5ITVJ?
SCC-15 MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T6OGlEPTB;MUOuNlY2OSEQvF2= M1LGeHNCVkeHUh?=
NOS-1 NXnvVnVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVexWGxGUUN3ME2xN{4zQDl|IN88US=> NYC2RY5mW0GQR1XS
RH-1 NEKwZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF|LkOwN|ch|ryP NV7HbGJlW0GQR1XS
SK-MEL-3 M3z2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCycXY{UUN3ME2xN{4{PzJ6IN88US=> NGLqZW9USU6JRWK=
NB5 MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF|LkSwOlch|ryP M1PoVnNCVkeHUh?=
SNU-387 NULsT4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LVbWlEPTB;MUOuOVA4OiEQvF2= MXnTRW5ITVJ?
CAL-120 NYTqRWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HCVWlEPTB;MUOuOlcyQCEQvF2= NFPZTHNUSU6JRWK=
Mo-T MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv0TWM2OD1zMz63NFch|ryP NIC0ZWxUSU6JRWK=
LNCaP-Clone-FGC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvIZZpCUUN3ME2xN{44QTl{IN88US=> MkLJV2FPT0WU
CAN Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnVTYZoUUN3ME2xOE4xOjh6IN88US=> M4r0W3NCVkeHUh?=
SK-MEL-30 NEmxZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3ld5o2UUN3ME2xOE4xPjNizszN MnrLV2FPT0WU
COLO-678 M{LSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\OUWVKSzVyPUG0MlA5OjJizszN M4DkbnNCVkeHUh?=
SCC-9 NUnOXno4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3wTWM2OD1zND6xNFIyKM7:TR?= M1\yZnNCVkeHUh?=
KINGS-1 NFTN[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rZSmlEPTB;MUSuNVQxOiEQvF2= MoXtV2FPT0WU
SL-513 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLYTWM2OD1zND6xPFch|ryP MYLTRW5ITVJ?
HLE M2XwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF2LkO4OVIh|ryP NVvzVW9OW0GQR1XS
SW1573 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPXZXg{UUN3ME2xOE41PDN3IN88US=> MV3TRW5ITVJ?
KYSE-140 MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjYNmtKSzVyPUG0MlY{OjdizszN NWKxOWI5W0GQR1XS
SK-PN-DW NWHaOYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Duc2lEPTB;MUSuPFAxOSEQvF2= M3XQR3NCVkeHUh?=
A253 M2XRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P1VmlEPTB;MUWuNFYzPSEQvF2= NHq1XlRUSU6JRWK=
CAL-12T MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3noW2lEPTB;MUWuOFY3OiEQvF2= NYKzUolwW0GQR1XS
COLO-679 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF3Lke2PFMh|ryP NFjvZ|BUSU6JRWK=
UACC-257 M{DOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF4LkGyNFEh|ryP MkjVV2FPT0WU
U-87-MG NXzrV|ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fVVGlEPTB;MU[uN|UzOyEQvF2= NEX3V29USU6JRWK=
HCC1806 Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfmRVNOUUN3ME2xOk44ODdzIN88US=> MVXTRW5ITVJ?
NCI-H2170 NYGxU3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr0[W5KSzVyPUG3MlI1PDhizszN MoLZV2FPT0WU
AGS NW\j[HdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DtdWlEPTB;MUeuN|gxQCEQvF2= NHThSZZUSU6JRWK=
MEL-HO M{n3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\k[WlEPTB;MUeuO|UxOyEQvF2= MlLNV2FPT0WU
SW48 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHBU|lKSzVyPUG3Mlc4OTZizszN M2Lx[HNCVkeHUh?=
HuP-T4 M2Cw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TJNGlEPTB;MUiuNFIxPiEQvF2= NHLiNoNUSU6JRWK=
NCI-H720 NX3VVJo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nGZWlEPTB;MUiuNVQxOiEQvF2= NVXyXZdlW0GQR1XS
RCC10RGB NEPX[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS3WJJKSzVyPUG4MlE3QTdizszN M{jpXXNCVkeHUh?=
HD-MY-Z Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnuZWVKSzVyPUG4MlIzPTRizszN NGWzPFhUSU6JRWK=
A427 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF6LkWwPVQh|ryP MUTTRW5ITVJ?
HCC2998 M{LXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXQW|JKSzVyPUG4MlYxPTFizszN M{TRSnNCVkeHUh?=
EPLC-272H NV7N[YU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF7LkC0N|Qh|ryP MnnsV2FPT0WU
C32 M1vBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGeyfGxKSzVyPUG5MlA1PSEQvF2= NVfLPVE{W0GQR1XS
UMC-11 NXTEZYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP2TWM2OD1zOT6yNVI{KM7:TR?= M2PTcHNCVkeHUh?=
CaR-1 M2[3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHjeVhvUUN3ME2xPU43QDB2IN88US=> MUDTRW5ITVJ?
KYSE-410 NXixWXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTGTWM2OD1zOT65NVM6KM7:TR?= MYPTRW5ITVJ?
HuCCT1 NGq1dXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrjdIhZUUN3ME2yNE43Ojl2IN88US=> MUnTRW5ITVJ?
LB996-RCC NW\JW206T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK3bWJKSzVyPUKwMlcyPjhizszN NVHNfFlHW0GQR1XS
KYSE-70 M33DdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJyLkiwOVkh|ryP M{jJTHNCVkeHUh?=
CAL-72 M3zvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJyLkmxOUDPxE1? NWG0OIZ4W0GQR1XS
Capan-2 NXrFfIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rC[GlEPTB;MkGuNFQyOyEQvF2= NEnCNXhUSU6JRWK=
PANC-08-13 M2G1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i0VmlEPTB;MkGuNlUyPSEQvF2= MX;TRW5ITVJ?
SBC-1 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn5V4tKSzVyPUKxMlMxQDFizszN NXPZTJpVW0GQR1XS
MFM-223 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJzLkOzOFIh|ryP MVPTRW5ITVJ?
BB49-HNC M4\LT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknvTWM2OD1{MT61O|E3KM7:TR?= M3\KZXNCVkeHUh?=
SH-4 Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofSTWM2OD1{MT62OlE5KM7:TR?= MUfTRW5ITVJ?
HuO9 M16xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjndYJKSzVyPUKxMlk5OjVizszN NU\0bVRtW0GQR1XS
AM-38 NVTX[VVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJ{LkC0PFUh|ryP Mn\FV2FPT0WU
A431 M17QR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;vTWM2OD1{Mz6yNVE6KM7:TR?= MnjhV2FPT0WU
YAPC NV3UOoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzKZXRKSzVyPUKzMlI3PTFizszN MUfTRW5ITVJ?
LU-139 M2rQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfPdFhlUUN3ME2yN{41QDB7IN88US=> M{\nZ3NCVkeHUh?=
HEC-1 NGe5RZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHyzOm9KSzVyPUKzMlQ6OzdizszN NXnEfol2W0GQR1XS
SCC-25 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\Kc4NKSzVyPUK0MlMxODZizszN MlPrV2FPT0WU
HT-29 NYL3T3o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ2LkO4NlMh|ryP MXPTRW5ITVJ?
PC-14 M2KwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ2Lk[1O|Eh|ryP NGTSRldUSU6JRWK=
Calu-6 NFHCcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPyTGV2UUN3ME2yOU42ODdzIN88US=> MkSyV2FPT0WU
SJRH30 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ3Lk[0PVYh|ryP MlrDV2FPT0WU
ChaGo-K-1 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;aVmNFUUN3ME2yOk4yPjJ7IN88US=> MYDTRW5ITVJ?
IA-LM MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7oTWM2OD1{Nj6zOlQ2KM7:TR?= M2HidHNCVkeHUh?=
GP5d NIjtdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTPTWM2OD1{Nj60OFkyKM7:TR?= NIji[2dUSU6JRWK=
NCI-H2291 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33lc2lEPTB;Mk[uOlU1OSEQvF2= M{\xWnNCVkeHUh?=
BALL-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzzW5IzUUN3ME2yOk46Ozl5IN88US=> NUXlNXdjW0GQR1XS
HCC1954 Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyyTWM2OD1{Nj65PFA5KM7:TR?= NF;6fJFUSU6JRWK=
NCI-H2452 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJ5LkSxOlMh|ryP NYDuR4k3W0GQR1XS
LU-99A NGO3ZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnqd|dKSzVyPUK3MlU2QDJizszN NWDkNZBJW0GQR1XS
NTERA-S-cl-D1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj2TWM2OD1{Nz63Nlk6KM7:TR?= MWfTRW5ITVJ?
PANC-10-05 NHHaWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXW[3ZKSzVyPUK3Mlc4PzVizszN MW\TRW5ITVJ?
NCI-H2405 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK2cZZXUUN3ME2yO{46Ozh5IN88US=> NIfTcHpUSU6JRWK=
MDA-MB-415 M4CxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHLepRKSzVyPUK4MlQyOzdizszN M1:4OXNCVkeHUh?=
NCI-H2342 NEjwdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13WWmlEPTB;MkiuOVI5OSEQvF2= MVXTRW5ITVJ?
TGBC24TKB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\HZppKSzVyPUK4MlcyOTdizszN MnXuV2FPT0WU
LU-134-A M3\D[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD2ZXl5UUN3ME2yPE46OjZzIN88US=> M3LnfHNCVkeHUh?=
SCC-4 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNzLkC0PVQh|ryP MkLxV2FPT0WU
Saos-2 M2f4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr5bVhKSzVyPUOxMlk{ODZizszN MX7TRW5ITVJ?
RERF-LC-MS NEfWfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTFPIRHUUN3ME2zNk45OjNzIN88US=> M1uwVXNCVkeHUh?=
M14 NXy4WG94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTNOZRHUUN3ME2zNk46PzZ2IN88US=> NGL4[WxUSU6JRWK=
HPAF-II M1jYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nVcGlEPTB;M{OuOVAyOSEQvF2= NXKzR2dNW0GQR1XS
NCI-H1755 NF3JWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHUTWM2OD1|ND6zN|A2KM7:TR?= MWXTRW5ITVJ?
D-392MG NHK2SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXLSXJSUUN3ME2zOU45Pjd2IN88US=> NF\LT5JUSU6JRWK=
A704 M1HMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnx[3BKSzVyPUO2MlA1OjdizszN MXjTRW5ITVJ?
CP50-MEL-B MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljlTWM2OD1|Nj6xPVEyKM7:TR?= M4[2fnNCVkeHUh?=
EW-18 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq1dnV6UUN3ME2zOk41PTJizszN MVrTRW5ITVJ?
WM-115 NInoVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjYfYVDUUN3ME2zOk45ODl7IN88US=> MmflV2FPT0WU
LU-65 M17kO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN5LkG0NVch|ryP MmHjV2FPT0WU
NCI-H1563 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr0TWM2OD1|Nz6yOFg1KM7:TR?= M161O3NCVkeHUh?=
DBTRG-05MG NVju[YNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zJZWlEPTB;M{iuNFY6OSEQvF2= MULTRW5ITVJ?
NCI-H630 M1PIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP1TWM2OD1|OD60O|E1KM7:TR?= M2foVHNCVkeHUh?=
NCI-H1155 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfwVVExUUN3ME2zPU4zPDJizszN MUPTRW5ITVJ?
OVACR-3 NXrTNWlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:1TWM2OD1|OT65NVk2KM7:TR?= NYXxfoNYW0GQR1XS
OAW-42 NUjsdol3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTRyLkSyOVgh|ryP NGPOeYNUSU6JRWK=
JVM-2 NF7yO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRzLkK0NVUh|ryP Mk\iV2FPT0WU
C3A MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LlcGlEPTB;NEGuN|Q1PyEQvF2= NEDQTYNUSU6JRWK=
HT55 NW\oRYFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ntb2lEPTB;NEKuNlg1OSEQvF2= NGT3UJFUSU6JRWK=
OVCAR-4 NWPYb3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLmfmJXUUN3ME20Nk4zQTd2IN88US=> M17zS3NCVkeHUh?=
MEG-01 NWHSZZAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDyTWM2OD12Mj60OlE3KM7:TR?= NIH0Z3BUSU6JRWK=
NCI-H82 NFW0bINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD0TWM2OD12Mz65PFkzKM7:TR?= M4m0cHNCVkeHUh?=
JEG-3 NYCy[|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTR2Lkm0O{DPxE1? NYraSnB6W0GQR1XS
BPH-1 NGDGNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[5TWM2OD12Nj6zPVk5KM7:TR?= Mnu1V2FPT0WU
MPP-89 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XHVmlEPTB;NEeuNlg6QCEQvF2= NVPsS|BZW0GQR1XS
ALL-PO NYr6dZVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zUT2lEPTB;NEeuOFE5QCEQvF2= NUHvRWQ{W0GQR1XS
HT MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjzd5RKSzVyPUS3MlQ6OiEQvF2= NWi0elNOW0GQR1XS
NCI-H2347 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfHZY83UUN3ME20PE4xPzF3IN88US=> NYTN[lRFW0GQR1XS
A2780 NFr5OWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG5eJR2UUN3ME20PU41OjJ6IN88US=> M{XKd3NCVkeHUh?=
KARPAS-299 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTR7LkWxNVkh|ryP NXfxfGVTW0GQR1XS
NCI-H1651 NIfSbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\NPG5KSzVyPUS5Mlg5OjFizszN MlH3V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
Saline
For best results, use promptly after mixing.
20 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID